Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
about
Review of advanced catheter technologies in radiation oncology brachytherapy proceduresGuidelines by the AAPM and GEC-ESTRO on the use of innovative brachytherapy devices and applications: Report of Task Group 167.A brief look at model-based dose calculation principles, practicalities, and promiseModel-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.Seed coordinates of a new COMS-like 24 mm plaque verified using the FARO Edge.Episcleral eye plaque dosimetry comparison for the Eye Physics EP917 using Plaque Simulator and Monte Carlo simulation.Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye.Multidimensional dosimetry of ¹⁰⁶Ru eye plaques using EBT3 films and its impact on treatment planning.Visual acuity, oncologic, and toxicity outcomes with 103Pd vs. 125I plaque treatment for choroidal melanoma.Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity.(103)Pd versus (125)I ophthalmic plaque brachytherapy: preoperative comparative radiation dosimetry for 319 uveal melanomasIndependent dosimetric assessment of the model EP917 episcleral brachytherapy plaque.Point/Counterpoint. Particle therapy is ideal for the treatment of ocular melanomas.I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films.Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.Magnetic resonance imaging metal artifact reduction for eye plaque patient with dental braces.Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.Novel application of 3D printing in brachytherapy using MED610 3D printed insert for I-125 ROPES eye plaque.Evaluation of material heterogeneity dosimetric effects using radiochromic film for COMS eye plaques loaded with (125)I seeds (model I25.S16).Evaluation of dose enhancement in presence of gold nanoparticles in eye brachytherapy by 103Pd source.Monte Carlo study for designing a dedicated "D"-shaped collimator used in the external beam radiotherapy of retinoblastoma patients.Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma.Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study.Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses.Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part IRadiobiological doses, tumor, and treatment features influence on outcomes after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part IIA practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using I COMS plaques
P2860
Q26800257-E2ECD5B3-CE8B-4EB2-86DD-A6F042797519Q30151984-EE7499FE-196E-4F63-8515-9F10572E2340Q37694566-1342F99B-A13F-4838-9387-AE9023E8BC5BQ38186120-F64C1295-D737-4FBA-95CF-A14D567A26BAQ38193210-4C957BFA-C26D-421F-A762-A468E0EEBF2FQ40176335-89F62530-C8DD-4901-9B7A-5F5A1F19932CQ40176373-621A7699-0937-4FA0-9F02-3D673C57CD89Q40176784-CDA4B42F-06CB-45E6-B9B1-FC8CB32A2FD2Q40475327-64B80695-65B4-4962-9890-504C0B6DAA44Q41625689-ACA704AC-DB66-436B-A752-465C12642A8FQ41824320-31D1C020-931C-42CB-BB5F-12114C6C505EQ42037875-A9E43E8F-F787-4F28-9AAA-4BC9F9722F93Q42465010-DC939D4B-51B3-42C9-91DD-5F9CC847AC04Q44112923-871C9925-AAAE-4F03-89B9-C01F7731FA0EQ46747884-965ED17D-0E4B-43FB-9D56-7C89429AAB4BQ46809059-7E77AF7D-0674-4B06-B4B9-FF3515A4A11EQ47142432-2CF21570-AB61-4957-A587-62A93EECFB73Q47724293-5E30C5F9-01F0-40EF-9FEF-A86EFB60575CQ48307127-EC047F54-05A6-4AEF-B52E-3FE5ADB8AF7BQ49021743-6FDAA655-C4B3-45EA-8C12-2C8D5D0EF985Q50644112-80E07A3E-DFE1-4191-B80F-84AE2B187D50Q50737160-F2D22D8B-B63F-4F68-9BB4-067E18E2335CQ55030160-261151BF-FE10-4EE7-BF52-6B2BAF6546AFQ55034746-BD2AAA4A-CCE0-4E0F-BE96-73168EB202F2Q55221185-5B481AB3-5A39-41A1-9E5E-2D9DE8062185Q58779687-77EE4111-BABD-4D25-B627-39F224396DD1Q58779720-45AB4B94-14E9-4E0E-9F8F-40AA27976327Q59127189-8A05DD1D-D786-4C4E-B527-1817DCC97907
P2860
Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dosimetry of (125)I and (103)P ...... Group 129 by the AAPM and ABS.
@en
type
label
Dosimetry of (125)I and (103)P ...... Group 129 by the AAPM and ABS.
@en
prefLabel
Dosimetry of (125)I and (103)P ...... Group 129 by the AAPM and ABS.
@en
P2093
P2860
P356
P1433
P1476
Dosimetry of (125)I and (103)P ...... Group 129 by the AAPM and ABS
@en
P2093
Ali S Meigooni
D W O Rogers
David S Followill
Firas Mourtada
Mark J Rivard
Mary E Napolitano
Melvin A Astrahan
Ravinder Nath
Rowan M Thomson
Sou-Tung Chiu-Tsao
P2860
P304
P356
10.1118/1.4749933
P407
P577
2012-10-01T00:00:00Z